Duodenojejunal Bypass Plus Sleeve Gastrectomy Reduces Infiltration of Macrophages and Secretion of TNF-α in the Visceral White Adipose Tissue of Goto-Kakizaki Rats

  • Hao Yu
  • Zhigao Song
  • Hongbin Zhang
  • Kehong Zheng
  • Junfang Zhan
  • Qing Luo
  • Jingbo Sun
  • Li Liang
  • Xiaojiang DaiEmail author
  • Liangping Wu
Original Contributions



Current studies indicate that inflammation of white adipose tissue (WAT) is a pathogenic characteristic of insulin resistance. However, the significance of visceral WAT inflammation after bariatric surgery remains unclear.


Duodenojejunal bypass plus sleeve gastrectomy (DJB-SG) was performed on Goto-Kakisaki rats. Weight, fasting blood glucose (FBG), and homeostatic model assessment of insulin resistance (HOMA-IR) in the DJB-SG group were compared to those in a sham surgery (SHAM) group every 2 weeks. The results of an oral glucose tolerance test (OGTT) and the volume of visceral adipose tissue (Visc.Fat) were compared before and 8 weeks postsurgery. Eight weeks after surgery, the rats were sacrificed and visceral WAT collected from the greater omentum. Tumor necrosis factor-α (TNF-α) and cluster of differentiation 68 (CD68) expression in the WAT were evaluated in paraffin-embedded sections by immunohistochemistry.


Compared with the SHAM group, the DJB-SG group demonstrated a significant reduction in weight, FBG, and HOMA-IR (P < 0.05), with elevation of insulin levels (P < 0.05) from 4 weeks after surgery. OGTT and the quantity of Visc.Fat were significantly reduced (P < 0.05) 8 weeks after surgery. Moreover, the expression of TNF-α and CD68 in the visceral white adipose tissue was significantly lower 8 weeks after surgery (P < 0.05).


The DJB-SG model established in Goto-Kakisaki rats achieved anticipated efficacy. Reduced TNF-α-related inflammation in visceral WAT may result in improved insulin resistance.


DJB-SG Insulin resistance Inflammation T2D 


Funding Information

This work was supported by the Science and Technology Planning Project of Guangzhou, China (Nos. 201508020002 and 201604020106), and the Science and Technology Planning Project of Guangdong Province, China (No. 2017ZC0324).

Compliance with Ethical Standards

Conflict of Interest

Hao Yu, Zhigao Song, Hongbin Zhang, Kehong Zheng, Junfang Zhan,Jingbo Sun, Zhizhi Wang, Lucas Zellmer, Xiaojiang Dai, Wu Liangping declare that they have no conflicts of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of Guangzhou General Hospital of Guangzhou Military Command’s research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

All applicable Guangzhou General Hospital of Guangzhou Military Command’s guidelines for the care and use of animals were followed.

Statement of Animal Rights

All animal experimental procedures involved in this study were approved by the Animal Care and Utilization Committee of Guangzhou General Hospital of Guangzhou Military Command.


  1. 1.
    Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76.CrossRefGoogle Scholar
  2. 2.
    Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377:1143–55.CrossRefGoogle Scholar
  3. 3.
    Sanchez-Pernaute A et al. Proximal duodenal-ileal end-to-side bypass with sleeve gastrectomy: proposed technique. Obes Surg. 2007;17:1614–8.CrossRefGoogle Scholar
  4. 4.
    Kasama K, Tagaya N, Kanehira E, et al. Laparoscopic sleeve gastrectomy with duodenojejunal bypass: technique and preliminary results. Obes Surg. 2009;19:1341–5.CrossRefGoogle Scholar
  5. 5.
    Lee WJ, Lee KT, Kasama K, et al. Laparoscopic single-anastomosis duodenal-jejunal bypass with sleeve gastrectomy (SADJB-SG): short-term result and comparison with gastric bypass. Obes Surg. 2014;24:109–13.CrossRefGoogle Scholar
  6. 6.
    Navarrete SA, Leyba JL, Llopis SN. Laparoscopic sleeve gastrectomy with duodenojejunal bypass for the treatment of type 2 diabetes in non-obese patients: technique and preliminary results. Obes Surg. 2011;21:663–7.CrossRefGoogle Scholar
  7. 7.
    Astiarraga B, Gastaldelli A, Muscelli E, et al. Biliopancreatic diversion in nonobese patients with type 2 diabetes: impact and mechanisms. J Clin Endocrinol Metab. 2013;98:2765–73.CrossRefGoogle Scholar
  8. 8.
    Heneghan HM, Nissen S, Schauer PR. Gastrointestinal surgery for obesity and diabetes: weight loss and control of hyperglycemia. Curr Atheroscler Rep. 2012;14:579–87.CrossRefGoogle Scholar
  9. 9.
    Severino A, Castagneto-Gissey L, Raffaelli M, et al. Early effect of roux-en-Y gastric bypass on insulin sensitivity and signaling. Surg Obes Relat Dis. 2016;12:42–7.CrossRefGoogle Scholar
  10. 10.
    Masoodi M, Kuda O, Rossmeisl M, et al. Lipid signaling in adipose tissue: Connecting inflammation &amp; metabolism. Biochim Biophys Acta. 2015;1851:503–18.CrossRefGoogle Scholar
  11. 11.
    Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116:1494–505.CrossRefGoogle Scholar
  12. 12.
    Moraes-Vieira PM, Yore MM, Dwyer PM, et al. RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance. Cell Metab. 2014;19:512–26.CrossRefGoogle Scholar
  13. 13.
    Borst SE. The role of TNF-alpha in insulin resistance. Endocrine. 2004;23:177–82.CrossRefGoogle Scholar
  14. 14.
    Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9.CrossRefGoogle Scholar
  15. 15.
    Hill AM, LaForgia J, Coates AM, et al. Estimating abdominal adipose tissue with DXA and anthropometry. Obesity (Silver Spring). 2007;15:504–10.CrossRefGoogle Scholar
  16. 16.
    Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239(1):1–11.CrossRefGoogle Scholar
  17. 17.
    Breen DM, Rasmussen BA, Kokorovic A, et al. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med. 2012;18:950–5.CrossRefGoogle Scholar
  18. 18.
    Jurowich CF, Rikkala PR, Thalheimer A, et al. Duodenal-jejunal bypass improves glycemia and decreases SGLT1-mediated glucose absorption in rats with streptozotocin-induced type 2 diabetes. Ann Surg. 2013;258:89–97.CrossRefGoogle Scholar
  19. 19.
    Gavin TP, Sloan RC, Lukosius EZ, et al. Duodenal-jejunal bypass surgery does not increase skeletal muscle insulin signal transduction or glucose disposal in Goto-Kakizaki type 2 diabetic rats. Obes Surg. 2011;21:231–7.CrossRefGoogle Scholar
  20. 20.
    Elffers TW et al. Body fat distribution, in particular visceral fat, is associated with cardiometabolic risk factors in obese women. PLoS One. 2017;e185403:12.Google Scholar
  21. 21.
    Jablonowska-Lietz B, Wrzosek M, Wlodarczyk M, et al. New indexes of body fat distribution, visceral adiposity index, body adiposity index, waist-to-height ratio, and metabolic disturbances in the obese. Kardiol Pol. 2017;75:1185.CrossRefGoogle Scholar
  22. 22.
    Lee SW, Son JY, Kim JM, et al. Body fat distribution is more predictive of all-cause mortality than overall adiposity. Diabetes Obes Metab. 2018;20:141–7.CrossRefGoogle Scholar
  23. 23.
    Taniguchi A, Nakai Y, Sakai M, et al. Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients. METABOLISM. 2002;51:544–8.CrossRefGoogle Scholar
  24. 24.
    Ko GTC, Tang JSF. Waist circumference and BMI cut-off based on 10-year cardiovascular risk: evidence for “central pre-obesity”. OBESITY. 2007;15:2832–9.CrossRefGoogle Scholar
  25. 25.
    Wang J, Thornton JC, Russell M, et al. Asians have lower body mass index (BMI) but higher percent body fat than do whites: comparisons of anthropometric measurements. Am J Clin Nutr. 1994;60:23–8.CrossRefGoogle Scholar
  26. 26.
    Baron SH. Salicylates as hypoglycemic agents. Diabetes Care. 1982;5:64–71.CrossRefGoogle Scholar
  27. 27.
    Allison MA, Jensky NE, Marshall SJ, et al. Sedentary behavior and adiposity-associated inflammation: the Multi-Ethnic Study of Atherosclerosis. Am J Prev Med. 2012;42:8.CrossRefGoogle Scholar
  28. 28.
    Ctoi AF et al. Metabolically healthy versus unhealthy morbidly obese: chronic inflammation, nitro-oxidative stress, and insulin resistance. Nutrients. 2018;10Google Scholar
  29. 29.
    Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes. 1999;107:119.CrossRefGoogle Scholar
  30. 30.
    Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389:610.CrossRefGoogle Scholar
  31. 31.
    Hotamisligil GS et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271:665–70.CrossRefGoogle Scholar
  32. 32.
    Plomgaard P, Bouzakri K, Krogh-Madsen R, et al. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. DIABETES. 2005;54:2939–45.CrossRefGoogle Scholar
  33. 33.
    Bouzakri K, Zierath JR. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem. 2007;282:7783–9.CrossRefGoogle Scholar
  34. 34.
    Li J, Tang Y, Cai D. IKKbeta/NF-kappaB disrupts adult hypothalamic neural stem cells to mediate a neurodegenerative mechanism of dietary obesity and pre-diabetes. Nat Cell Biol. 2012;14:999–1012.CrossRefGoogle Scholar
  35. 35.
    van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth J Med. 2013;71:174.Google Scholar
  36. 36.
    Leon-Pedroza JI et al. Low-grade systemic inflammation and the development of metabolic diseases: from the molecular evidence to the clinical practice. Cir Cir. 2015;83:543–51.Google Scholar
  37. 37.
    Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 2012;11:201–14.CrossRefGoogle Scholar
  38. 38.
    Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation. 2003;108:414–9.CrossRefGoogle Scholar
  39. 39.
    Trak-Smayra V, Dargere D, Noun R, et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut. 2009;58:825–32.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Special Medical Service CenterZhujiang Hospital of Southern Medical UniversityGuangzhouChina
  2. 2.Southern Medical UniversityGuangzhouChina
  3. 3.Department of Metabolic Surgery,Guangzhou General Hospital of Guangzhou Military CommandGuangzhouChina
  4. 4.Physical Examination CenterGuangzhou First People’s HospitalGuangzhouChina
  5. 5.Department of Metabolic SurgeryUDM Medical GroupGuangzhouChina
  6. 6.Abdominal surgeryJinshazhou Hospital of Guangzhou University of Traditional Chinese MedicineGuangzhouChina

Personalised recommendations